Last reviewed · How we verify
IncobotulinumtoxinA 100 UNT Injection [Xeomin]
IncobotulinumtoxinA 100 UNT Injection [Xeomin] is a Botulinum toxin Small molecule drug developed by University Of Perugia. It is currently in Phase 3 development for Cervical dystonia, Blepharospasm, Hemifacial spasm. Also known as: Incobot/A.
IncobotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
IncobotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.
At a glance
| Generic name | IncobotulinumtoxinA 100 UNT Injection [Xeomin] |
|---|---|
| Also known as | Incobot/A |
| Sponsor | University Of Perugia |
| Drug class | Botulinum toxin |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Small molecule |
| Therapeutic area | Neurology, Dermatology, Aesthetics |
| Phase | Phase 3 |
Mechanism of action
IncobotulinumtoxinA is a botulinum toxin serotype A that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, resulting in localized muscle weakness or paralysis. The effect is temporary, typically lasting 3-4 months, after which neuromuscular function gradually recovers.
Approved indications
- Cervical dystonia
- Blepharospasm
- Hemifacial spasm
- Glabellar lines (wrinkles)
- Spasticity
Common side effects
- Injection site pain or bruising
- Headache
- Muscle weakness or paralysis (off-target)
- Ptosis (eyelid drooping)
- Dry mouth
- Neck pain
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IncobotulinumtoxinA 100 UNT Injection [Xeomin] CI brief — competitive landscape report
- IncobotulinumtoxinA 100 UNT Injection [Xeomin] updates RSS · CI watch RSS
- University Of Perugia portfolio CI
Frequently asked questions about IncobotulinumtoxinA 100 UNT Injection [Xeomin]
What is IncobotulinumtoxinA 100 UNT Injection [Xeomin]?
How does IncobotulinumtoxinA 100 UNT Injection [Xeomin] work?
What is IncobotulinumtoxinA 100 UNT Injection [Xeomin] used for?
Who makes IncobotulinumtoxinA 100 UNT Injection [Xeomin]?
Is IncobotulinumtoxinA 100 UNT Injection [Xeomin] also known as anything else?
What drug class is IncobotulinumtoxinA 100 UNT Injection [Xeomin] in?
What development phase is IncobotulinumtoxinA 100 UNT Injection [Xeomin] in?
What are the side effects of IncobotulinumtoxinA 100 UNT Injection [Xeomin]?
What does IncobotulinumtoxinA 100 UNT Injection [Xeomin] target?
Related
- Drug class: All Botulinum toxin drugs
- Target: All drugs targeting SNAP-25 (synaptosome-associated protein of 25 kDa)
- Manufacturer: University Of Perugia — full pipeline
- Therapeutic area: All drugs in Neurology, Dermatology, Aesthetics
- Indication: Drugs for Cervical dystonia
- Indication: Drugs for Blepharospasm
- Indication: Drugs for Hemifacial spasm
- Also known as: Incobot/A
- Compare: IncobotulinumtoxinA 100 UNT Injection [Xeomin] vs similar drugs
- Pricing: IncobotulinumtoxinA 100 UNT Injection [Xeomin] cost, discount & access